Bandhan Mutual Fund quietly crosses 5% in EPL, Cyient, and Mastek
Over September 2026, Bandhan Mutual Fund crossed the 5% regulatory disclosure threshold in three completely unrelated companies — a packaging maker, an engineering-services firm, and an IT services company. Each disclosure trickled out separately, but the underlying accumulation pattern was very different in each: a large purchase in EPL, versus a gradual, month-by-month build in Cyient and Mastek.
EPL Limited - Share price: ₹238 - Market cap: ~₹7,627 crore - P/E: 18.6x — vs. Cosmo First ~13.6x, Uflex ~6.9x; one tracker's packaging-sector average ~21x
Cyient Limited - Share price: ₹1,095 - Market cap: ~₹12,168 crore - P/E: 29.9x — vs. KPIT Technologies ~22-28x, Tata Elxsi ~35x
Mastek Limited - Share price: ₹1,583 - Market cap: ~₹4,908 crore - P/E: 11.2x — vs. Zensar Technologies ~12x; one tracker's IT-services sector average ~19x
(All prices, market caps and P/E ratios above are screener.in's own figures as of the September 25, 2026 market close — September 26 is a Saturday with no new trading. Check the live price before acting.)
Three very different buys, one fund house
EPL Limited (formerly Essel Propack), incorporated in 1982, makes the flexible plastic tubes you squeeze to get toothpaste, face cream, or shampoo out — it doesn't make the products inside, just the tube packaging, sold to multinational customers like Colgate, Unilever, and L'Oréal. It runs plants across India, Poland, Germany, Thailand, and other countries to serve customers locally. The regulatory disclosure shows Bandhan Mutual Fund (across its various schemes) bought 58,64,986 shares of EPL through the open market on September 1, 2026, taking its combined holding from 3.4773% to 5.3083% (1,70,03,191 shares total). The exchange bulk-deal data captures one piece of that day's buying — 20,82,465 shares at ₹240 — but the regulatory filing is the complete picture.
EPL's Q1 FY27 earnings call described it as the company's fifth consecutive quarter of double-digit revenue growth and 15th consecutive quarter of double-digit EBITDA growth — management called it a "record performance." The company is deliberately shifting away from its legacy Oral Care business toward Beauty & Cosmetics tube packaging (higher-margin, faster-growing), which along with Personal Care now makes up 54% of its portfolio, up from a historically Oral Care-dominated mix. It currently holds just 8% of the global Beauty & Cosmetics tube market and is targeting a doubling of that share.
Cyient Limited, incorporated in 1991 (originally as Infotech Enterprises) by B.V.R. Mohan Reddy, provides engineering and technology services across four segments — Digital, Engineering & Technology (DET, covering aerospace, rail, connectivity and utilities design work), Design-Led Manufacturing (electronics manufacturing services), Semiconductors (chip design and supply-chain management), and an Aerospace Tooling division. Monthly portfolio disclosures show the buying here wasn't a single event: Bandhan Small Cap Fund — one specific scheme within the AMC — has been adding Cyient shares almost every month since March 2025, most recently 3,50,603 shares at ₹854.30 on July 31, 2026. The 5.03% disclosure around September 3 is the latest milestone in a year-long accumulation, not a one-off trade.
Mastek Limited, incorporated in 1982 (originally as Management and Software Technology), is one of India's oldest listed IT services companies. It specialises in Oracle Cloud implementations and digital transformation, with an especially deep footprint in UK public-sector work — long-standing relationships with the NHS, the Ministry of Justice, and 30+ UK local councils. Like Cyient, this is a Bandhan Small Cap Fund story: the scheme has bought Mastek shares in every single month from March 2025 through July 2026, at prices ranging from about ₹1,451 to ₹2,391 — buying through a sharp fall and the beginnings of a recovery. A further purchase of 18,000 shares around September 15 took the combined Bandhan holding from 4.9964% to 5.0544%, triggering the disclosure.
Bandhan built one large single-day position in EPL, but built up its Cyient and Mastek stakes gradually, month after month, through a single small-cap scheme.
The numbers: growth doesn't mean the same thing everywhere
All three companies reported Q1 FY27 (April-June 2026) results, but the growth-versus-profit picture looks different for each:
Company Q1 FY27 Revenue YoY Growth Q1 FY27 Profit Profit trend --------------- EPL ₹1,387.9 cr +25.3% ₹98.6 cr Down ~1.4% YoY — pre-tax profit actually grew 10%; a higher effective tax rate (22% vs 18% a year ago) ate into it Cyient ₹2,076 cr +7.7% QoQ ₹104 cr Up 90% QoQ — but from a weak Q4FY26 base (₹55 cr); core DET segment revenue was down 0.9% YoY in constant currency Mastek ₹985.3 cr +7.7% YoY ₹105.9 cr Up 15% YoY — the most balanced Q1 of the three, but management flags margin pressure ahead (see below)
EPL's headline revenue growth looks the strongest of the three, but its profit (PAT) actually declined. The higher effective tax rate (18% to 22%) explains most of the gap between its 10% pre-tax profit growth and the small PAT decline, though EBITDA also grew slower than revenue (15.2% vs 25.3%), so some operating-margin pressure was at work too — not purely a tax story. Cyient's sharp profit rebound looks dramatic, but it's largely a low-base effect: profit had fallen hard in the prior quarter, and its core engineering-services (DET) segment revenue was down slightly in constant currency (-0.9% YoY, -0.5% QoQ) — note Cyient also reports a normalised consolidated PAT of ₹114 crore excluding one-off M&A-related effects, above the ₹104 crore reported figure. Mastek is the only one of the three where revenue and profit grew together at a similar pace in Q1 — though that's this article's own read of the numbers, not a claim management itself makes.
A single quarter's percentage jump means very little without knowing what it's being compared against.
How they're priced against listed peers
Company P/E (Sept 25 close) Nearest listed peers Peer P/E ------------ EPL 18.6x Cosmo First, Uflex ~13.6x, ~6.9x (one tracker's sector avg ~21x) Cyient 29.9x KPIT Technologies, Tata Elxsi ~22-28x, ~35x Mastek 11.2x Zensar Technologies ~12x (one tracker's IT-services sector avg ~19x)
None of the three looks dramatically mispriced against its peer group. EPL, at 18.6x, sits above Cosmo First and well above Uflex, but is below the packaging-sector average quoted by at least one tracker (~21x) — a moderate, not extreme, valuation; "sector average" varies by source depending on which peers are included, so treat it as directional. Cyient's 29.9x sits comfortably inside the range set by KPIT Technologies and Tata Elxsi — squarely mid-pack for its industry, not an outlier in either direction. Mastek, at 11.2x, is priced close to Zensar and below at least one cited IT-services sector average (~19x) — the cheapest of the three on this measure, though its own management has flagged margin pressure into Q2 (see below).
Always check a company's P/E against its own listed peers before deciding "cheap" or "expensive" — a number that looks extreme in isolation can turn out to be entirely ordinary for its sector.
What each company's own management is telling investors
These are the companies' own forward-looking statements from their latest earnings calls and investor presentations — management's stated targets and outlook, not verified facts or guarantees:
EPL: - Revenue growth guidance raised from "early/low double digits" to a 16-18% ("high teens") range for the next few quarters, on Beauty & Cosmetics momentum, an Oral Care recovery, and the Thailand plant ramping up. - Underlying EBITDA margin target held at 20% (currently 19.6%); management says "on a steady-state basis, our EBITDA will grow faster than our revenue growth." - Double-digit PAT growth still expected for full-year FY27, despite the Q1 dip caused by the tax-rate jump. - Beauty & Cosmetics global market share target: doubling from the current 8% to 16% "in the next few years." - The pending Indovida merger (CCI-approved, final approval awaited) would add rigid-plastics capability and entry into Southeast Asia and Africa — management calls it "very, very EPS accretive," with Indovida's own Q1 PAT comparable to EPL's. - Europe margins, currently below the mid-teens target due to manufacturing-consolidation costs in Poland, are expected to recover "in coming quarters" (no specific date given).
Cyient: - Management gave no explicit numeric revenue or profit targets for FY27 or FY28 at its August 2026 Investor Day. - Stated ambition: build a combined group revenue base of roughly $1 billion, including the Kinetic Technologies (~$40 million revenue, closed April 2026) and TAO Digital Solutions (~$80 million revenue, expected to close Q2 FY27) acquisitions. - A Large Deals pipeline exceeding $300 million and 5 large-deal wins in Q1 FY27, cited as evidence of demand. - Strategic shift across all three business lines (engineering services, electronics manufacturing, and semiconductors) toward owning intellectual property rather than billing for engineering hours — management frames this as moving from "throughput"-based to "what it owns"-based valuation. - Capital allocation policy: up to 50% of PAT returned to shareholders, with an average 67% payout ratio (dividends + buybacks) over the past six years.
Mastek: - Management explicitly declined to give formal margin guidance for FY27, but confirmed Q2 will face further margin headwinds — new ESOP grants and salary increments estimated at $400,000-$500,000 per quarter starting Q2. - CEO Umang Nahata: "We believe our FY27 performance should be better than FY26." - North America is targeted to become a genuine growth engine by H2 FY27, needing to scale to a $28-30 million quarterly run-rate to reach mid-teen margins — it's currently sub-scale. - The UK's NHS England healthcare vertical, which dipped in Q1 on a project transition, is expected to return to sequential growth from Q2 FY27. - A $25 million, 5-year Salesforce Agentforce AI deal won in North America — one of the company's largest ever — is expected to ramp up in H2 FY27.
Growth guidance and margin guidance are two different promises — a company can raise one while quietly warning about the other. EPL raised its revenue outlook while flagging a tax-driven profit dip. Mastek is upbeat on the year overall while explicitly warning its next quarter's margins will be worse. Read both halves before deciding what "guidance" actually tells you.
Should you follow this into your own portfolio?
Buying alongside a large mutual fund isn't a strategy by itself — a 5% disclosure only tells you a fund has built a large position, not that the stock is cheap or that its own reasons match yours. Of the three:
- EPL is a long-established company that has grown steadily for decades, with genuinely strong operating momentum right now — raised revenue guidance, a large pending merger management calls earnings-accretive — priced moderately (below at least one cited packaging-sector average) even after a quarter where reported profit dipped on a tax-rate jump. - Cyient is priced right in the middle of its engineering-services peer group, not at any kind of extreme. The real question here is whether its core DET segment returns to growth and whether the pending TAO acquisition closes on schedule — not the headline multiple. Management itself gave no numeric guidance to anchor expectations against. - Mastek is the cheapest of the three relative to its closest peer, with the most balanced Q1 growth — but management has explicitly flagged its own next quarter's margins will be worse, from ESOP costs, salary increments, and ongoing Middle East disruption. Cheapest isn't the same as risk-free.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://www.investywise.com/bandhan-amc-acquisition-disclosure - https://www.investywise.com/bandhan-amc-disclosure-of-share-acquisition-in-cyient-limited - https://www.investywise.com/bandhan-amc-equity-acquisition-disclosure - https://www.screener.in/company/EPL/consolidated/ - https://www.screener.in/company/CYIENT/consolidated/ - https://www.screener.in/company/MASTEK/consolidated/ - https://www.msn.com/en-in/money/economy/bandhan-mutual-fund-buys-58-65-lakh-epl-shares-raises-stake-to-5-3/ar-AA2buKYN - https://www.whalesbook.com/company/announcements/MASTEK - https://www.cyient.com/news/2026/7/cyient-delivers-resilient-q1-performance-led-by-continued-growth-in-transportation-and-mobility - https://www.valueresearchonline.com/stocks/41678/cosmo-first-ltd/peer-comparison/ - https://www.valueresearchonline.com/stocks/44961/uflex-ltd/peer-comparison/ - https://www.wisesheets.io/pe-ratio/KPITTECH.NS - https://www.wisesheets.io/pe-ratio/TATAELXSI.NS - https://www.gurufocus.com/term/pettm/NSE:ZENSARTECH - https://en.wikipedia.org/wiki/EsselPropack - https://en.wikipedia.org/wiki/Cyient - https://www.mastek.com/our-story/ - https://www.sahi.com/news/epl-reports-q1-consolidated-net-profit-of-986m-rupees-versus-1b-yoy-91-PE1CORPO - https://upstox.com/news/market-news/earnings/cyient-q1-fy-27-results-net-profit-rises-90-revenue-grows-to-2-076-crore-qo-q/article-197472/ - https://www.freepressjournal.in/business/mastek-q1-fy27-net-profit-rises-15-yoy-to-1062-crore-revenue-grows-to-938-crore